Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS
NCT ID: NCT00161681
Last Updated: 2013-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
200 participants
INTERVENTIONAL
2005-07-31
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder
NCT00128934
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT00245921
Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception
NCT00248963
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
NCT00195559
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT02021097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levonorgestrel/Ethinyl Estradiol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regular 21 to 35 day menstrual cycles for 3 months prior to study visit 1
* History of menstrual cycle related symptoms as determined by the investigator.
Exclusion Criteria
* Depression requiring hospitalization or associated with suicidal ideation within the last 3 years
* Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.
18 Years
49 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor, MD
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville, Alabama, United States
Peoria, Arizona, United States
Phoenix, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
San Diego, California, United States
Denver, Colorado, United States
Longmont, Colorado, United States
Aventura, Florida, United States
Boynton Beach, Florida, United States
Clearwater, Florida, United States
DeLand, Florida, United States
Fort Myers, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Pembroke Pines, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Savannah, Georgia, United States
Idaho Falls, Idaho, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Lexington, Kentucky, United States
Kansas City, Missouri, United States
Las Vegas, Nevada, United States
Las Vegas, Nevada, United States
Moorestown, New Jersey, United States
Rochester, New York, United States
Fayetteville, North Carolina, United States
Winston-Salem, North Carolina, United States
Cleveland, Ohio, United States
Mogadore, Ohio, United States
Eugene, Oregon, United States
Medford, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Wexford, Pennsylvania, United States
Hilton Head Island, South Carolina, United States
Mt. Pleasant, South Carolina, United States
Nashville, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Sandy City, Utah, United States
Richmond, Virginia, United States
Lakewood, Washington, United States
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B3121024
Identifier Type: OTHER
Identifier Source: secondary_id
0858A2-322
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.